SEC Form 4 · accession 0001209191-18-010129
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart A Arbuckle
Officer — EVP\Chief Commercial Officer
Period of report
Feb 12, 2018
Accepted (ET)
Feb 14, 2018 · 6:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Feb 12, 2018 | S | 875 | $150.78 | D | 61,650 | D | |
| Common StockF2,F4 | Feb 12, 2018 | S | 800 | $152.27 | D | 60,850 | D | |
| Common StockF2,F5 | Feb 12, 2018 | S | 3,879 | $153.07 | D | 56,971 | D | |
| Common StockF2,F6 | Feb 12, 2018 | S | 1,270 | $153.80 | D | 55,701 | D | |
| Common Stock | holding | — | — | — | 140 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.
- F2Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $150.78 (range $150.42 to $151.20).
- F4Open market sales reported on this line occurred at a weighted average price of $152.27 (range $151.67 to $152.62).
- F5Open market sales reported on this line occurred at a weighted average price of $153.07 (range $152.67 to $153.66).
- F6Open market sales reported on this line occurred at a weighted average price of $153.80 (range $153.67 to $153.99).